Table 2.
Oral glucocorticoid exposure over follow-up intervals, grouped by total parenteral glucocorticoid dose received over follow-up interval
| Total dose of parenteral GC, mga | n (%) of FUI where PO GCs have been used | Median point estimatesb | |||
|---|---|---|---|---|---|
| Total PO GC dose, mg | Average daily PO GC dose, mg | Maximum daily PO GC dose, mg | Total time on PO GC, days | ||
| >1000 (n = 182) | 172 (94.5) | 5503 | 15.0 | 30 | 371 |
| 250–1000 (n = 90) | 80 (88.9) | 4663 | 10.0 | 30 | 365 |
| <250 (n = 175) | 109 (62.3) | 2688 | 7.5 | 10 | 336 |
| 0 (n = 10287) | 6097 (59.3) | 2450 | 6.0 | 10 | 364 |
| P-value for between group comparisons | <0.001* | <0.001** | <0.001** | <0.001** | 0.015** |
a
Information on total parenteral GC dose available for 10 734 follow-up intervals.
b
Median values calculated from those FUIs where PO GCs have been used; that is, dose or duration equal to zero not included in the calculation.
*
Chi-square.
**
Kruskal–Wallis. FUI: follow-up interval; GC: glucocorticoid; PO: oral.